Two Yale Pathology Faculty Among 12 Honored with 2022 Yale Faculty Innovation Awards
Two Yale Pathology professors were among 12 faculty members honored with 2022 Yale Faculty Innovation Awards, which recognize the significant contributions of Yale faculty who develop new technologies and launch startups that address global challenges.
Yale scientists identify key defect in brain tumor cells
In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.
Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer
Researchers at Yale think they've come up with a new way to treat a certain kind of brain tumor using a drug that's already been approved by the FDA. In a study published Wednesday in the journal Science Translational Medicine, the researchers outline a hypothesis for using the drug to tackle brain cancer. Thing is, the hypothesis they put forward is the exact opposite of the one other scientists, as well as several drug companies including Agios Pharmaceuticals, had previously been working with. The drug they discuss, called a PARP inhibitor, blocks a protein our cells use to repair DNA and kill off tumors. In certain kinds of cancer, that repair system is broken, which allows cancer cells to thrive.Source: Yahoo Finance
Platelet response to influenza vaccination reflects effects of aging
A paper whose authors include several Yale School of Medicine professors, researchers and scientists recently made the cover of Aging Cell. The cover design is by Hannah Wang, Academic Support Associate, Department of Pathology.Source: Aging Cell
New Data Reported From Trials of Drug Developed at Yale Pathology to Treat Rare, Often Fatal Neonatal Disorder
Clinical trial data from an enzyme-therapy drug developed at Yale Pathology to treat a rare and often fatal neonatal calcification disorder were recently reported. The drug, INZ-701, was designed and validated in the laboratory of Demetrios Braddock, MD, PhD, Associate Professor of Pathology at Yale School of Medicine.
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
Yale Cancer Center Study Characterizes Link Between Drug Resistance and Central Nervous System Relapse
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
Patient Selection for AstraZeneca, Daiichi Breast Cancer Drug Needs Improvement, Experts Say
The rush to use AstraZeneca and Daiichi-Sankyo’s drug Enhertu to treat certain types of breast cancer has far outpaced doctors’ ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.Source: Financial Post
Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.Source: SABCS Meeting News
Yale Pathologists to Collaborate with African Physicians at Inaugural PEACE Symposium
A partnership that began at Emory University to allow pathologists to collaborate and share knowledge with physicians in Africa has expanded to include Yale School of Medicine pathologists and will hold its first symposium in December.